Received Nov 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Shingrix late second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 54-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 17-DEC-2020 with batch number C47FY and 2A3HY). On 13-JAN-2025, the patient received the 2nd dose of Shingrix. On 13-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 11-NOV-2025 The pharmacy intern wanted to know how to proceed with a patient that received the first dose of Shingrix on 17-DEC-2020 and the second on 13-JAN-2025. The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter.